Back to Search Start Over

Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.

Authors :
Tung YC
Lin YS
Wu LS
Chang CJ
Chu PH
Source :
Journal of clinical hypertension (Greenwich, Conn.) [J Clin Hypertens (Greenwich)] 2015 Jan; Vol. 17 (1), pp. 51-8. Date of Electronic Publication: 2014 Dec 05.
Publication Year :
2015

Abstract

This retrospective claims database analysis compared two strategies of hypertension treatment in outpatient, emergency, and inpatient departments: a fixed-dose combination (FDC) of amlodipine/valsartan vs free combinations of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) (ARB+CCB group). After a mean follow-up of 15.2 months, the FDC group had significantly lower total healthcare costs (US $1844 vs US $2158; P<.001) and hospitalization rates (14.57% vs 18.43%; P<.001), a higher proportion of days covered (80.35% vs 72.57%; P<.001), and better persistence (266 vs 225 days; P<.001) compared with the ARB+CCB group. The FDC group also had a better major adverse cardiovascular event (MACE)-free survival (hazard ratio, 0.83; 95% confidence interval, 0.73-0.94; P=.003) and decreased rates of heart failure (2.12% vs 3.26%; P<.001), malignant dysrhythmia (0.18% vs 0.42%; P=.021), and percutaneous coronary intervention (0.76% vs 1.26%; P=.015). Compared with free combinations of ARB+CCB, an FDC of amlodipine/valsartan improved MACE-free survival and medication compliance and decreased total healthcare costs and hospitalization rates in hypertensive patients.<br /> (© 2014 Wiley Periodicals, Inc.)

Details

Language :
English
ISSN :
1751-7176
Volume :
17
Issue :
1
Database :
MEDLINE
Journal :
Journal of clinical hypertension (Greenwich, Conn.)
Publication Type :
Academic Journal
Accession number :
25477188
Full Text :
https://doi.org/10.1111/jch.12449